サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1701807

ワクチン市場：技術別、患者タイプ別、適応症別、投与経路別、製品タイプ別、治療タイプ別、エンドユーザー別、流通チャネル別、地域別、2025-2033年

Vaccine Market Report by Technology, Patient Type, Indication, Route of Administration, Product Type, Treatment Type, End User, Distribution Channel, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 144 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
ワクチン市場：技術別、患者タイプ別、適応症別、投与経路別、製品タイプ別、治療タイプ別、エンドユーザー別、流通チャネル別、地域別、2025-2033年
出版日: 2025年04月01日
発行: IMARC
ページ情報: 英文 144 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ワクチン市場の世界市場規模は2024年に598億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに1,365億米ドルに達し、2025年から2033年にかけて9.12%の成長率（CAGR）を示すと予測しています。個人へのワクチン接種を促進する厳しい規制の実施、バイオテクノロジーやワクチン市場開拓技術のいくつかの進歩、ワクチン接種の重要性に関する国民の健康意識の高まりなどが、市場を推進している主な要因の一部です。

ワクチンは、感染症の蔓延を予防・制御するために設計された、公衆衛生に不可欠なツールです。ワクチンは基本的に生物学的製剤であり、細菌やウイルスなどの特定の病原体を認識し、それと闘うよう免疫系を刺激します。ワクチンには、抗原として知られる標的病原体やその断片の弱毒化または不活化したものが含まれています。ワクチン接種を行うと、感染症を模倣し、免疫系に抗体を産生させ、免疫記憶を発達させる。さらに、実際の病原体にさらされた場合、免疫系が速やかに防御を開始し、病気を効果的に予防したり、重症度を軽減したりします。

この市場を牽引しているのは、主に個人の健康に対する関心の高まりです。また、コロナウイルス感染症（COVID-19）のパンデミックが最近発生したことで、公衆衛生を守る上でこの製品が重要であるという認識が個人間で高まり、市場の成長を後押ししています。さらに、mRNA製品のような新しいワクチン技術の開発は、より迅速かつ正確なワクチン開発能力を提供することで業界に変革をもたらし、新たな脅威に効果的に対処しています。このほか、製薬企業はワクチンポートフォリオを拡大し、従来の疾患以外にもさまざまな疾患の予防接種を行うことで、新たな市場と収益源を開拓し、販売需要を加速させています。これとともに、ワクチン接種の推進、国民の意識向上キャンペーン、疾病の蔓延を抑えるためのワクチン研究への資金提供など、いくつかの政府の取り組みが市場の成長を後押ししています。さらに、官民で進められているワクチン研究開発投資（R&D）により、新製品の強力なパイプラインが確保されているため、市場の見通しは明るいです。

ワクチン市場動向/促進要因：

ワクチン接種を促進する厳格な規制の実施

この市場を牽引しているのは、ワクチン接種の普及を目的とした厳格な規制の施行です。さらに、ワクチンの安全性と有効性が重視されるようになっていることも、市場の成長を後押ししています。さらに、メーカー各社は、製品が最高水準の安全性を満たすことを保証するため、厳格な試験と品質管理対策に取り組んでおり、その結果、病気を効果的に予防し、副作用の少ない製品を生み出すための研究開発（R&D）への投資が増加しています。このほか、企業は潜在的な副作用や禁忌を含め、製品に関する明確で包括的な情報を提供することで、個人が十分な情報を得た上でワクチン接種を決定できるようになり、製品の普及率が加速しています。これとともに、さまざまな政府や医療当局が、補助金、啓発キャンペーン、場合によっては義務化など、ワクチン接種を奨励するさまざまなインセンティブプログラムを実施しており、市場の成長を後押ししています。

バイオテクノロジーとワクチン開発技術のいくつかの進歩

市場は、バイオテクノロジーとワクチン開発技術におけるいくつかの目覚ましい進歩によって牽引されています。バイオテクノロジーとワクチン開発技術の進歩は、予防接種の設計や製造方法を変革し、非常に有効で標的を絞った予防接種の開発に貢献しています。さらに、ワクチン開発におけるゲノミクスと分子生物学の活用により、科学者たちはかつてないスピードと精度で病原体の遺伝情報を解読できるようになり、潜在的なワクチン候補をより効率的に特定できるようになりました。さらに、組換えデオキシリボ核酸（DNA）技術のいくつかの進歩は、組換えワクチン接種の作成を可能にし、B型肝炎やヒトパピローマウイルスなどの感染症の予防に効果的な病気そのものを引き起こすことなく、強化された免疫反応を刺激します。さらに、合成生物学技術の応用もいくつかの革新に寄与しており、科学者は課題病原体に対する新規予防接種の開発のために、ワクチン成分を正確に設計・合成することができます。

ワクチン接種の重要性に対する意識の高まり

この市場を牽引しているのは、ワクチン接種の重要性に関する個人の健康意識の高まりです。さらに、最近のコロナウイルス感染症（COVID-19）の大流行により、ワクチン接種の価値に関する一般市民の意識が高まり、市場の成長が加速しています。これに伴い、新興国市場は、ワクチンの有効性、安全性、入手しやすさを重視しながら、ウイルスと闘うための予防接種を開発・配布しており、市場の成長を促進しています。さらに、公衆衛生を守るために、医療プロバイダー、政府機関、メディアなど、さまざまなチャネルを通じて正確な情報を発信していることも、大きな成長促進要因となっています。これに加えて、ソーシャルメディアやデジタル・プラットフォームの台頭は、予防接種に関する情報提供に重要な役割を果たし、個人が信頼できるリソースにアクセスし、情報に基づいた議論に参加することを可能にしています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向
    • 規制状況
      • 米国
      • カナダ
      • 欧州連合
      • 中国
      • インド
      • 日本
      • 韓国
      • オーストラリア
      • ロシア
      • ブラジル
      • メキシコ
      • トルコ
      • GCC諸国
      • イスラエル
    • 新しいワクチンの製品パイプライン
      • HIVの製品パイプライン
      • ジカウイルスの製品パイプライン
      • エボラウイルスの製品パイプライン
      • COVID-19関連製品パイプライン

第5章 世界のワクチン市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：技術別

  • 結合ワクチン
  • 不活化ワクチンとサブユニットワクチン
  • 生弱毒化ワクチン
  • 組換えワクチン
  • トキソイドワクチン
  • その他

第7章 市場内訳：患者タイプ別

  • 小児
  • 成人

第8章 市場内訳：適応症別

  • 細菌性疾患
    • 主な種類
      • 髄膜炎菌感染症
      • 肺炎球菌感染症
      • ジフテリア・破傷風・百日咳（DPT）
      • 結核
      • インフルエンザ菌（Hib）
      • 腸チフス
      • その他
  • ウイルス性疾患
    • 主な種類
      • 肝炎
      • インフルエンザ
      • ヒトパピローマウイルス（HPV）
      • 麻疹・おたふく風邪・風疹（MMR）
      • ロタウイルス
      • 帯状疱疹
      • 水痘
      • 日本脳炎
      • 風疹
      • ポリオ
      • 狂犬病
      • デング熱
      • その他

第9章 市場内訳：投与経路別

  • 筋肉内・皮下投与
  • 経口投与
  • その他

第10章 市場内訳：製品タイプ別

  • 多価ワクチン
  • 一価ワクチン

第11章 市場内訳：治療タイプ別

  • 予防ワクチン
  • 治療ワクチン

第12章 市場内訳：エンドユーザー別

  • 病院
  • クリニック
  • ワクチン接種センター
  • 学術研究機関
  • その他

第13章 市場内訳：流通チャネル別

  • 病院薬局
  • 小売薬局
  • 機関販売
  • その他

第14章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • トルコ
    • GCC諸国
    • イスラエル
    • その他

第15章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第16章 バリューチェーン分析

  • 探索段階
  • 前臨床および臨床開発
  • 規制当局の承認
  • 製造
  • マーケティングと流通

第17章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第18章 価格分析

第19章 主な促進要因と課題

第20章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • Bharat Biotech International
    • Bavarian Nordic A/S
    • CSL Limited
    • Daiichi Sankyo Company Limited
    • Emergent BioSolutions Inc.
    • GlaxoSmithKline Plc
    • Inovio Pharmaceuticals Inc.
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Mitsubishi Tanabe Pharma Corporation（Mitsubishi Chemical Holdings Corporation）
    • Novavax Inc.
    • Panacea Biotec Ltd.
    • Pfizer Inc.
    • Sanofi Pasteur SA（Sanofi SA）
    • Serum Institute of India Pvt. Ltd.
    • Takeda Pharmaceutical Company Limited
図表

List of Figures

  • Figure 1: Global: Vaccine Market: Major Drivers and Challenges
  • Figure 2: Global: Vaccine Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Vaccine Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Vaccine Market: Breakup by Technology (in %), 2024
  • Figure 5: Global: Vaccine Market: Breakup by Patient Type (in %), 2024
  • Figure 6: Global: Vaccine Market: Breakup by Indication (in %), 2024
  • Figure 7: Global: Vaccine Market: Breakup by Route of Administration (in %), 2024
  • Figure 8: Global: Vaccine Market: Breakup by Product Type (in %), 2024
  • Figure 9: Global: Vaccine Market: Breakup by Treatment Type (in %), 2024
  • Figure 10: Global: Vaccine Market: Breakup by End User (in %), 2024
  • Figure 11: Global: Vaccine Market: Breakup by Distribution Channel (in %), 2024
  • Figure 12: Global: Vaccine Market: Breakup by Region (in %), 2024
  • Figure 13: Global: Vaccine (Conjugate Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Vaccine (Conjugate Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Vaccine (Inactivated and Subunit Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Vaccine (Inactivated and Subunit Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Vaccine (Live Attenuated Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Vaccine (Live Attenuated Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Vaccine (Recombinant Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Vaccine (Recombinant Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Vaccine (Toxoid Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Vaccine (Toxoid Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Vaccine (Other Technologies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Vaccine (Other Technologies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Vaccine (Paediatric) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Vaccine (Paediatric) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Vaccine (Adult) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Vaccine (Adult) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Vaccine (Bacterial Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Vaccine (Bacterial Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Vaccine (Meningococcal Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Vaccine (Meningococcal Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Vaccine (Pneumococcal Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Vaccine (Pneumococcal Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Vaccine (Diphtheria/Tetanus/Pertussis-DPT) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Vaccine (Diphtheria/Tetanus/Pertussis-DPT) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Vaccine (Tuberculosis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Vaccine (Tuberculosis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Vaccine (Haemophilus Influenzae-Hib) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Vaccine (Haemophilus Influenzae-Hib) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Vaccine (Typhoid) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Vaccine (Typhoid) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Global: Vaccine (Other Bacterial Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Global: Vaccine (Other Bacterial Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Global: Vaccine (Viral Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Global: Vaccine (Viral Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Global: Vaccine (Hepatitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Global: Vaccine (Hepatitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Global: Vaccine (Influenza) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Global: Vaccine (Influenza) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Global: Vaccine (Human Papillomavirus-HPV) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Global: Vaccine (Human Papillomavirus-HPV) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Global: Vaccine (Measles/Mumps/Rubella-MMR) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Global: Vaccine (Measles/Mumps/Rubella-MMR) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Global: Vaccine (Rotavirus) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Global: Vaccine (Rotavirus) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Global: Vaccine (Herpes Zoster) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Global: Vaccine (Herpes Zoster) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Global: Vaccine (Varicella) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Global: Vaccine (Varicella) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Global: Vaccine (Japanese Encephalitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Global: Vaccine (Japanese Encephalitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Global: Vaccine (Rubella) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Global: Vaccine (Rubella) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Global: Vaccine (Polio) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Global: Vaccine (Polio) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Global: Vaccine (Rabies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Global: Vaccine (Rabies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Global: Vaccine (Dengue) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Global: Vaccine (Dengue) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Global: Vaccine (Other Viral Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Global: Vaccine (Other Viral Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Global: Vaccine (Intramuscular and Subcutaneous Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Global: Vaccine (Intramuscular and Subcutaneous Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Global: Vaccine (Oral Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Global: Vaccine (Oral Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Vaccine (Other Routes of Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Global: Vaccine (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Global: Vaccine (Multivalent Vaccine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Global: Vaccine (Multivalent Vaccine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Global: Vaccine (Monovalent Vaccine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Global: Vaccine (Monovalent Vaccine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Global: Vaccine (Preventive Vaccine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Global: Vaccine (Preventive Vaccine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Global: Vaccine (Therapeutic Vaccine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Global: Vaccine (Therapeutic Vaccine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Global: Vaccine (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Global: Vaccine (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Global: Vaccine (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Global: Vaccine (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 91: Global: Vaccine (Vaccination Centres) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 92: Global: Vaccine (Vaccination Centres) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 93: Global: Vaccine (Academic and Research Institutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 94: Global: Vaccine (Academic and Research Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 95: Global: Vaccine (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 96: Global: Vaccine (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 97: Global: Vaccine (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 98: Global: Vaccine (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 99: Global: Vaccine (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 100: Global: Vaccine (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 101: Global: Vaccine (Institutional Sales) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 102: Global: Vaccine (Institutional Sales) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 103: Global: Vaccine (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 104: Global: Vaccine (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 105: North America: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 106: North America: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 107: United States: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 108: United States: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 109: Canada: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 110: Canada: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 111: Asia Pacific: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 112: Asia Pacific: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 113: China: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 114: China: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 115: Japan: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 116: Japan: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 117: India: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 118: India: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 119: South Korea: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 120: South Korea: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 121: Australia: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 122: Australia: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 123: Others: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 124: Others: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 125: Europe: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 126: Europe: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 127: Germany: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 128: Germany: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 129: France: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 130: France: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 131: United Kingdom: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 132: United Kingdom: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 133: Italy: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 134: Italy: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 135: Spain: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 136: Spain: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 137: Russia: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 138: Russia: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 139: Others: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 140: Others: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 141: Latin America: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 142: Latin America: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 143: Brazil: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 144: Brazil: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 145: Mexico: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 146: Mexico: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 147: Others: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 148: Others: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 149: Middle East and Africa: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 150: Middle East and Africa: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 151: Turkey: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 152: Turkey: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 153: GCC Countries: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 154: GCC Countries: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 155: Israel: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 156: Israel: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 157: Others: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 158: Others: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 159: Global: Vaccine Industry: SWOT Analysis
  • Figure 160: Global: Vaccine Industry: Value Chain Analysis
  • Figure 161: Global: Vaccine Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Vaccine Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Vaccine Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 3: Global: Vaccine Market Forecast: Breakup by Patient Type (in Million USD), 2025-2033
  • Table 4: Global: Vaccine Market Forecast: Breakup by Indication (in Million USD), 2025-2033
  • Table 5: Global: Vaccine Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 6: Global: Vaccine Market Forecast: Breakup by Product Type (in Million USD), 2025-2033
  • Table 7: Global: Vaccine Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
  • Table 8: Global: Vaccine Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 9: Global: Vaccine Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 10: Global: Vaccine Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 11: Global: Vaccine Market: Competitive Structure
  • Table 12: Global: Vaccine Market: Key Players
目次
Product Code: SR112025A2374

The global vaccine market size reached USD 59.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 136.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.12% during 2025-2033. The implementation of stringent regulations promoting the adoption of vaccination among individuals, several advances in biotechnology and vaccine development techniques, and the growing health awareness among the population about the importance of vaccination are some of the major factors propelling the market.

Vaccines are essential tools in public health, designed to prevent and control the spread of infectious diseases. They are essentially biological preparations that stimulate the immune system to recognize and fight specific pathogens, such as bacteria or viruses. They contain weakened or inactivated forms of the target pathogen or pieces of it, known as antigens. When administered, vaccination mimic an infection, prompting the immune system to produce antibodies and develop immune memory. Additionally, it ensures immune system to swiftly mount a defense, effectively preventing illness or reducing its severity, when the individual is exposed to the actual pathogen.

The market is primarily driven by the growing health concerns among individuals. In addition, the recent onset of the coronavirus disease (COVID-19) pandemic raised awareness among individuals regarding the importance of the product in safeguarding public health, thus augmenting the market growth. Moreover, the development of novel vaccine technologies, such as mRNA products are transforming the industry by offering faster and precise vaccine development capabilities, addressing emerging threats effectively, thus representing another major growth-inducing factor. Besides this, pharmaceutical companies are expanding their vaccine portfolios to include vaccinations for various diseases beyond the traditional ones which opened new markets and revenue streams, thus accelerating the sales demand. Along with this, several government initiatives including vaccination drives, public awareness campaigns, and funding for vaccine research to curb the spread of diseases are propelling the market growth. Furthermore, the ongoing vaccine research and development investment (R&D) in public and private sectors ensures a robust pipeline of new products, thus creating a positive market outlook.

Vaccine Market Trends/Drivers:

The implementation of stringent regulations promoting the adoption of vaccination

The market is driven by the enforcement of stringent regulations aimed at promoting vaccination among individuals. In addition, the growing emphasis on vaccine safety and efficacy is augmenting the market growth. Moreover, manufacturers adhere to rigorous testing and quality control measures to ensure that products meet the highest standards of safety, resulting in rising investment in research and development (R&D) to create products that prevent diseases effectively and have minimal adverse effects, thus representing another major growth-inducing factor. Besides this, companies are providing clear and comprehensive information about their products, including potential side effects and contraindications which empowers individuals to make informed decisions about vaccination, thus accelerating the product adoption rate. Along with this, various governments and healthcare authorities are implementing various incentive programs including subsidies, public awareness campaigns, and mandates in some cases encouraging the adoption of vaccination, thus propelling the market growth.

Several advances in biotechnology and vaccine development techniques

The market is driven by several remarkable advances in biotechnology and vaccine development techniques. It is transforming the way vaccinations are designed and manufactured which is contributing to the development of highly effective and targeted vaccinations. In addition, the utilization of genomics and molecular biology in vaccine development led scientists to decode the genetic information of pathogens with unprecedented speed and precision, enabling them to identify potential vaccine candidates more efficiently, resulting in the development of products against emerging diseases such as COVID-19, thus augmenting the market growth. Moreover, several advancements in recombinant deoxyribonucleic acid (DNA) technology allowed for the creation of recombinant vaccinations, stimulating enhanced immune response without causing the disease itself which is effective in preventing infectious diseases, including hepatitis B and human papillomavirus, thus representing another major growth-induing factor. Furthermore, the application of synthetic biology techniques is also contributing to several innovations, allowing scientists to design and synthesize vaccine components with precision, for the development of novel vaccinations against challenging pathogens, thus creating a positive market outlook.

The growing awareness about the importance of vaccination

The market is driven by the growing health awareness among individuals regarding the importance of vaccination. In addition, the recent onset of the coronavirus disease (COVID-19) pandemic raised public awareness about the value of vaccination, thus augmenting the market growth. Along with this, manufacturers are developing and distributing vaccinations to combat the virus while focusing on vaccine efficacy, safety, and accessibility, thus propelling the market growth. Moreover, the dissemination of accurate information through various channels, including healthcare providers, government agencies, and the media to safeguard public health, which represents another major growth-inducing factor. Besides this, the rise of social media and digital platforms played a significant part in providing information about vaccinations, enabling individuals to access reliable resources and engage in informed discussions.

Vaccine Industry Segmentation:

Breakup by Technology:

  • Conjugate Vaccines
  • Inactivated and Subunit Vaccines
  • Live Attenuated Vaccines
  • Recombinant Vaccines
  • Toxoid Vaccines
  • Others

Conjugate products are gaining popularity due to their effectiveness in preventing bacterial infections. They are designed to elicit a strong immune response and are particularly used for diseases such as haemophilus influenzae type B (Hib) and streptococcus pneumoniae.

Moreover, inactivated and subunit products are widely used for viral diseases, such as influenza, hepatitis B, and human papillomavirus (HPV) which contain components of the pathogen, ensuring safety while still providing immunity, thus representing another major growth-inducing factor. Besides this, Live attenuated vaccines are created from weakened forms of pathogens and are effective against diseases such as measles, mumps, and rubella which are essential in disease eradication programs, thus accelerating the sales demand.

Along with this, recombinant products use genetic engineering to create vaccinations against diseases such as hepatitis B and human papillomavirus and offer potential for customization and efficacy, thus propelling the market growth. Also, toxoid vaccinations are employed for bacterial diseases including diphtheria and tetanus due to their long-lasting immunity benefits, thus augmenting the market growth.

Breakup by Patient Type:

  • Pediatric
  • Adult

Pediatric patients hold the largest share of the market

The pediatrics segment is driven by the growing emphasis on immunization, thus influencing the market growth. Moreover, governments and healthcare organizations are preventing childhood diseases, leading to increasing vaccination programs and investments in pediatric vaccine research, thus contributing to market growth.

Moreover, several advancements in vaccine technology made it possible to develop safer and more effective vaccinations for children, resulting in a steady stream of new vaccinations tailored specifically for pediatric populations, representing another major growth-inducing factor.

Additionally, the COVID-19 pandemic underscored the importance of vaccinations for children. Efforts to vaccinate children against the virus further increase the role of pediatrics in the vaccine industry, thus propelling the market growth.

Breakup by Indication:

  • Bacterial Diseases
    • Meningococcal Disease
    • Pneumococcal Disease
    • Diphtheria/Tetanus/Pertussis (DPT)
    • Tuberculosis
    • Haemophilus Influenzae (Hib)
    • Typhoid
    • Others
  • Viral Diseases
    • Hepatitis
    • Influenza
    • Human Papillomavirus (HPV)
    • Measles/Mumps/Rubella (MMR)
    • Rotavirus
    • Herpes Zoster
    • Varicella
    • Japanese Encephalitis
    • Rubella
    • Polio
    • Rabies
    • Dengue
    • Others

Bacterial diseases presently account for the largest market share

The market is driven by the growing incidences of bacterial diseases, caused by various bacteria such as Streptococcus pneumoniae and Haemophilus influenzae. In addition, the increasing development of effective vaccinations to prevent these infections is augmenting the market growth.

Furthermore, several advancements in vaccine technology are improving bacterial disease vaccinations. Along with this, several innovations in research and development (R&D) yielded vaccinations that are effective and safe for widespread use which are designed to stimulate the body's immune response, thereby conferring immunity against bacterial pathogens, thus propelling the market growth.

Breakup by Route of Administration:

  • Intramuscular and Subcutaneous Administration
  • Oral Administration
  • Others

Intramuscular and subcutaneous administration represents the leading segment

Intramuscular administration involves injecting vaccinations directly into the muscle tissue which offers several advantages. In addition, muscles have an abundant blood supply, allowing for efficient uptake and distribution of the vaccine components leading to improved immune response, thus influencing the market growth. Along with this, IM injections often require larger needles, which can facilitate the administration of vaccinations with thicker formulations or those containing adjuvants, thus augmenting the market growth.

Moreover, subcutaneous administration involves injecting vaccinations into the fatty tissue just beneath the skin which is preferred for products that are well-suited for slower, sustained release into the bloodstream, thus representing another major growth-inducing factor. It is less invasive and typically uses smaller needles, making it a preferred choice among individuals who may be apprehensive about needles.

Breakup by Product Type:

  • Multivalent Vaccine
  • Monovalent Vaccine

Multivalent vaccine represent the most used product type

Multivalent offers a streamlined approach to immunization by combining antigens from different pathogens into a single vaccine, which reduces the number of injections required, minimizing discomfort for patients and simplifying vaccination schedules, thus augmenting the market growth.

Furthermore, multivalent vaccinations are efficient in preventing several diseases. For instance, combination vaccinations such as the measles, mumps, and rubella (MMR) vaccinations are eliminating these diseases in many regions, resulting in extensive research and development (R&D) efforts in the field, thus propelling the market growth.

Along with this, multivalent vaccinations offer substantial advantages, as the production, distribution, and administration of a single vaccine covering multiple diseases are more efficient and economical compared to individual vaccinations for each pathogen, thus accelerating the product adoption rate among healthcare systems and patients.

Breakup by Treatment Type:

  • Preventive Vaccine
  • Therapeutic Vaccine

Preventive vaccine currently dominates the market

Preventive vaccinations are designed to proactively protect individuals from contracting specific diseases. They achieve this by stimulating the immune system to produce antibodies that recognize and neutralize pathogens, such as viruses or bacteria, should the individual be exposed to them in the future has proven to be highly effective in reducing the incidence and severity of various illnesses.

Moreover, it has immense success in eradicating or controlling life-threatening diseases. Some historical examples include the near-eradication of smallpox through vaccination and the significant reduction in polio cases which are essential in fighting against infectious diseases. Furthermore, the rapid development and distribution of products to combat the virus and save countless lives are propelling the market growth.

Breakup by End User:

  • Hospitals
  • Clinics
  • Vaccination Centers
  • Academic and Research Institutes
  • Others

Hospitals hold the largest share of the market

The hospital industry is driven by its strategic position as a primary healthcare provider. In addition, hospitals serve as the frontline of defense against infectious diseases, making them the ideal setting for vaccine dissemination which possesses the necessary infrastructure, medical personnel, and resources to efficiently handle the storage, distribution, and administration of products, thus propelling the market growth.

Furthermore, hospitals are essential in vaccination advocacy and education. They are trusted sources of healthcare information, and their healthcare professionals serve as product advocates through patient consultations, seminars, and informational campaigns. Along with this, hospitals are promoting the importance of vaccination, contributing to higher vaccination rates and public awareness.

Along with this, hospitals also engage in product research and development (R&D), partnering with pharmaceutical companies and research institutions to conduct clinical trials and assess vaccination efficacy, thus contributing to market growth.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Institutional Sales
  • Others

Hospital pharmacies presently account for the largest market share

Hospital pharmacies are located at the heart of healthcare facilities which ensures that vaccinations are easily accessible to healthcare professionals and patients. Hospitals are often the first point of contact for individuals seeking vaccination, whether it's for routine immunizations or during public health emergencies.

Moreover, hospital pharmacies have the infrastructure and trained staff necessary to handle and administer products safely while adhering to strict quality control and storage protocols, ensuring the integrity and efficacy of vaccinations throughout the distribution process, thus representing another major growth-inducing factor. This reliability and commitment to maintaining the cold chain are essential for preserving the potency of products.

Along with this, hospital pharmacies benefit from established relationships with healthcare providers and government agencies responsible for vaccination programs which allows for seamless coordination in vaccination procurement, distribution, and administration, thus propelling the market growth. Also, hospitals serve as vaccination hubs during mass immunization campaigns, further solidifying their role in the market.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
    • Turkey
    • GCC Countries
    • Israel
    • Others

Asia Pacific exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific accounted for the largest market share.

The Asia Pacific market is driven by the growing pharmaceutical and biotechnology sector. In addition, several countries such as India and China are investing heavily in the development of their healthcare infrastructure, research capabilities, and manufacturing capacities, allowing them to produce vaccination at scale, often at a lower cost than their Western counterparts. thus, contributing to the market growth.

Additionally, the rising pool of skilled scientists, researchers, and healthcare professionals is augmenting the market growth. These experts are driving innovation and ensuring the quality and safety of vaccinations produced in the region. Furthermore, the region offers ample opportunities for clinical trials and testing, allowing for the accelerated development of new products, thus accelerating the sales demand.

Apart from this, the strategic partnerships and collaborations among pharmaceutical companies in the region are facilitating technology transfer, knowledge sharing, and access to critical resources, strengthening the region's position in the market.

Competitive Landscape:

At present, key players in the market are taking strategic initiatives to strengthen their positions in the competitive landscape of the market research and consulting services industry. These actions are vital for maintaining their relevance and authority in the field. They are embracing advanced technologies including artificial intelligence, machine learning, and data analytics which help in delivering more accurate and actionable insights, that is highly valued by clients. Moreover, companies are establishing thought leadership through content marketing and thought-provoking research reports which help in showcasing expertise and attract clients who seek industry insights. Besides this, they are focusing on client satisfaction and building long-term relationships by providing personalized services and tailored solutions based on client requirements that enhance trust and loyalty.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bharat Biotech International
  • Bavarian Nordic A/S
  • CSL Limited
  • Daiichi Sankyo Company Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline Plc
  • Inovio Pharmaceuticals Inc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
  • Novavax Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi Pasteur SA (Sanofi SA)
  • Serum Institute of India Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited.

Recent Developments:

  • In September 2020, the Serum Institute of India Pvt. Ltd., partnered with Gavi and the Bill & Melinda Gates Foundation to accelerate the production and distribution of an additional 100 million doses of COVID-19 vaccines that are safe and effective.
  • In April 2023, Pfizer Inc., announced data from phase 3 trials of its RSV shots. The trial conducted in adult patients demonstrated that the shot was 67% more effective in preventing infections with two related symptoms and 86% effective in case of severe disease. The successful approval of this vaccine will make it the first product in the RSV market.
  • In June 2022, GlaxoSmithKline Plc officially submitted a Biologics License Application (BLA) to the United States Food and Drug Administration (USFDA) for their experimental vaccine known as PRIORIX, which originally registered in Germany, has received licenses from more than 100 countries.

Key Questions Answered in This Report

  • 1.What was the size of the global vaccine market in 2024?
  • 2.What is the expected growth rate of the global vaccine market during 2025-2033?
  • 3.What are the key factors driving the global vaccine market?
  • 4.What has been the impact of COVID-19 on the global vaccine market?
  • 5.What is the breakup of the global vaccine market based on the patient type?
  • 6.What is the breakup of the global vaccine market based on the indication?
  • 7.What is the breakup of the global vaccine market based on the route of administration?
  • 8.What is the breakup of the global vaccine market based on the product type?
  • 9.What is the breakup of the global vaccine market based on the treatment type?
  • 10.What is the breakup of the global vaccine market based on the end user?
  • 11.What is the breakup of the global vaccine market based on the distribution channel?
  • 12.What are the key regions in the global vaccine market?
  • 13.Who are the key players/companies in the global vaccine market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends
    • 4.2.1 Regulatory Landscape
      • 4.2.1.1 United States
      • 4.2.1.2 Canada
      • 4.2.1.3 European Union
      • 4.2.1.4 China
      • 4.2.1.5 India
      • 4.2.1.6 Japan
      • 4.2.1.7 South Korea
      • 4.2.1.8 Australia
      • 4.2.1.9 Russia
      • 4.2.1.10 Brazil
      • 4.2.1.11 Mexico
      • 4.2.1.12 Turkey
      • 4.2.1.13 GCC Countries
      • 4.2.1.14 Israel
    • 4.2.2 Product Pipeline for New Vaccines
      • 4.2.2.1 Product Pipeline for HIV
      • 4.2.2.2 Product Pipeline for Zika Virus
      • 4.2.2.3 Product Pipeline for Ebola Virus
      • 4.2.2.4 Product Pipeline for COVID-19

5 Global Vaccine Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Conjugate Vaccines
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Inactivated and Subunit Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Live Attenuated Vaccines
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Recombinant Vaccines
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Toxoid Vaccines
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Patient Type

  • 7.1 Paediatric
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Adult
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Bacterial Diseases
    • 8.1.1 Market Trends
    • 8.1.2 Major Types
      • 8.1.2.1 Meningococcal Disease
        • 8.1.2.1.1 Market Trends
        • 8.1.2.1.2 Market Forecast
      • 8.1.2.2 Pneumococcal Disease
        • 8.1.2.2.1 Market Trends
        • 8.1.2.2.2 Market Forecast
      • 8.1.2.3 Diphtheria/Tetanus/Pertussis (DPT)
        • 8.1.2.3.1 Market Trends
        • 8.1.2.3.2 Market Forecast
      • 8.1.2.4 Tuberculosis
        • 8.1.2.4.1 Market Trends
        • 8.1.2.4.2 Market Forecast
      • 8.1.2.5 Haemophilus Influenzae (Hib)
        • 8.1.2.5.1 Market Trends
        • 8.1.2.5.2 Market Forecast
      • 8.1.2.6 Typhoid
        • 8.1.2.6.1 Market Trends
        • 8.1.2.6.2 Market Forecast
      • 8.1.2.7 Others
        • 8.1.2.7.1 Market Trends
        • 8.1.2.7.2 Market Forecast
    • 8.1.3 Market Forecast
  • 8.2 Viral Diseases
    • 8.2.1 Market Trends
    • 8.2.2 Major Types
      • 8.2.2.1 Hepatitis
        • 8.2.2.1.1 Market Trends
        • 8.2.2.1.2 Market Forecast
      • 8.2.2.2 Influenza
        • 8.2.2.2.1 Market Trends
        • 8.2.2.2.2 Market Forecast
      • 8.2.2.3 Human Papillomavirus (HPV)
        • 8.2.2.3.1 Market Trends
        • 8.2.2.3.2 Market Forecast
      • 8.2.2.4 Measles/Mumps/Rubella (MMR)
        • 8.2.2.4.1 Market Trends
        • 8.2.2.4.2 Market Forecast
      • 8.2.2.5 Rotavirus
        • 8.2.2.5.1 Market Trends
        • 8.2.2.5.2 Market Forecast
      • 8.2.2.6 Herpes Zoster
        • 8.2.2.6.1 Market Trends
        • 8.2.2.6.2 Market Forecast
      • 8.2.2.7 Varicella
        • 8.2.2.7.1 Market Trends
        • 8.2.2.7.2 Market Forecast
      • 8.2.2.8 Japanese Encephalitis
        • 8.2.2.8.1 Market Trends
        • 8.2.2.8.2 Market Forecast
      • 8.2.2.9 Rubella
        • 8.2.2.9.1 Market Trends
        • 8.2.2.9.2 Market Forecast
      • 8.2.2.10 Polio
        • 8.2.2.10.1 Market Trends
        • 8.2.2.10.2 Market Forecast
      • 8.2.2.11 Rabies
        • 8.2.2.11.1 Market Trends
        • 8.2.2.11.2 Market Forecast
      • 8.2.2.12 Dengue
        • 8.2.2.12.1 Market Trends
        • 8.2.2.12.2 Market Forecast
      • 8.2.2.13 Others
        • 8.2.2.13.1 Market Trends
        • 8.2.2.13.2 Market Forecast
    • 8.2.3 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Intramuscular and Subcutaneous Administration
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Oral Administration
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Product Type

  • 10.1 Multivalent Vaccine
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Monovalent Vaccine
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast

11 Market Breakup by Treatment Type

  • 11.1 Preventive Vaccine
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Therapeutic Vaccine
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast

12 Market Breakup by End User

  • 12.1 Hospitals
    • 12.1.1 Market Trends
    • 12.1.2 Market Forecast
  • 12.2 Clinics
    • 12.2.1 Market Trends
    • 12.2.2 Market Forecast
  • 12.3 Vaccination Centres
    • 12.3.1 Market Trends
    • 12.3.2 Market Forecast
  • 12.4 Academic and Research Institutes
    • 12.4.1 Market Trends
    • 12.4.2 Market Forecast
  • 12.5 Others
    • 12.5.1 Market Trends
    • 12.5.2 Market Forecast

13 Market Breakup by Distribution Channel

  • 13.1 Hospital Pharmacies
    • 13.1.1 Market Trends
    • 13.1.2 Market Forecast
  • 13.2 Retail Pharmacies
    • 13.2.1 Market Trends
    • 13.2.2 Market Forecast
  • 13.3 Institutional Sales
    • 13.3.1 Market Trends
    • 13.3.2 Market Forecast
  • 13.4 Others
    • 13.4.1 Market Trends
    • 13.4.2 Market Forecast

14 Market Breakup by Region

  • 14.1 North America
    • 14.1.1 United States
      • 14.1.1.1 Market Trends
      • 14.1.1.2 Market Forecast
    • 14.1.2 Canada
      • 14.1.2.1 Market Trends
      • 14.1.2.2 Market Forecast
  • 14.2 Asia Pacific
    • 14.2.1 China
      • 14.2.1.1 Market Trends
      • 14.2.1.2 Market Forecast
    • 14.2.2 Japan
      • 14.2.2.1 Market Trends
      • 14.2.2.2 Market Forecast
    • 14.2.3 India
      • 14.2.3.1 Market Trends
      • 14.2.3.2 Market Forecast
    • 14.2.4 South Korea
      • 14.2.4.1 Market Trends
      • 14.2.4.2 Market Forecast
    • 14.2.5 Australia
      • 14.2.5.1 Market Trends
      • 14.2.5.2 Market Forecast
    • 14.2.6 Others
      • 14.2.6.1 Market Trends
      • 14.2.6.2 Market Forecast
  • 14.3 Europe
    • 14.3.1 Germany
      • 14.3.1.1 Market Trends
      • 14.3.1.2 Market Forecast
    • 14.3.2 France
      • 14.3.2.1 Market Trends
      • 14.3.2.2 Market Forecast
    • 14.3.3 United Kingdom
      • 14.3.3.1 Market Trends
      • 14.3.3.2 Market Forecast
    • 14.3.4 Italy
      • 14.3.4.1 Market Trends
      • 14.3.4.2 Market Forecast
    • 14.3.5 Spain
      • 14.3.5.1 Market Trends
      • 14.3.5.2 Market Forecast
    • 14.3.6 Russia
      • 14.3.6.1 Market Trends
      • 14.3.6.2 Market Forecast
    • 14.3.7 Others
      • 14.3.7.1 Market Trends
      • 14.3.7.2 Market Forecast
  • 14.4 Latin America
    • 14.4.1 Brazil
      • 14.4.1.1 Market Trends
      • 14.4.1.2 Market Forecast
    • 14.4.2 Mexico
      • 14.4.2.1 Market Trends
      • 14.4.2.2 Market Forecast
    • 14.4.3 Others
      • 14.4.3.1 Market Trends
      • 14.4.3.2 Market Forecast
  • 14.5 Middle East and Africa
    • 14.5.1 Turkey
      • 14.5.1.1 Market Trends
      • 14.5.1.2 Market Forecast
    • 14.5.2 GCC Countries
      • 14.5.2.1 Market Trends
      • 14.5.2.2 Market Forecast
    • 14.5.3 Israel
      • 14.5.3.1 Market Trends
      • 14.5.3.2 Market Forecast
    • 14.5.4 Others
      • 14.5.4.1 Market Trends
      • 14.5.4.2 Market Forecast

15 SWOT Analysis

  • 15.1 Overview
  • 15.2 Strengths
  • 15.3 Weaknesses
  • 15.4 Opportunities
  • 15.5 Threats

16 Value Chain Analysis

  • 16.1 Exploratory Stage
  • 16.2 Preclinical and Clinical Development
  • 16.3 Regulatory Approval
  • 16.4 Manufacturing
  • 16.5 Marketing and Distribution

17 Porters Five Forces Analysis

  • 17.1 Overview
  • 17.2 Bargaining Power of Buyers
  • 17.3 Bargaining Power of Suppliers
  • 17.4 Degree of Competition
  • 17.5 Threat of New Entrants
  • 17.6 Threat of Substitutes

18 Price Analysis

19 Major Drivers and Challenges

20 Competitive Landscape

  • 20.1 Market Structure
  • 20.2 Key Players
  • 20.3 Profiles of Key Players
    • 20.3.1 Abbott Laboratories
      • 20.3.1.1 Company Overview
      • 20.3.1.2 Product Portfolio
      • 20.3.1.3 Financials
      • 20.3.1.4 SWOT Analysis
    • 20.3.2 Astellas Pharma Inc.
      • 20.3.2.1 Company Overview
      • 20.3.2.2 Product Portfolio
      • 20.3.2.3 Financials
      • 20.3.2.4 SWOT Analysis
    • 20.3.3 AstraZeneca Plc
      • 20.3.3.1 Company Overview
      • 20.3.3.2 Product Portfolio
      • 20.3.3.3 Financials
      • 20.3.3.4 SWOT Analysis
    • 20.3.4 Bharat Biotech International
      • 20.3.4.1 Company Overview
      • 20.3.4.2 Product Portfolio
    • 20.3.5 Bavarian Nordic A/S
      • 20.3.5.1 Company Overview
      • 20.3.5.2 Product Portfolio
      • 20.3.5.3 Financials
    • 20.3.6 CSL Limited
      • 20.3.6.1 Company Overview
      • 20.3.6.2 Product Portfolio
      • 20.3.6.3 Financials
      • 20.3.6.4 SWOT Analysis
    • 20.3.7 Daiichi Sankyo Company Limited
      • 20.3.7.1 Company Overview
      • 20.3.7.2 Product Portfolio
    • 20.3.8 Emergent BioSolutions Inc.
      • 20.3.8.1 Company Overview
      • 20.3.8.2 Product Portfolio
      • 20.3.8.3 Financials
      • 20.3.8.4 SWOT Analysis
    • 20.3.9 GlaxoSmithKline Plc
      • 20.3.9.1 Company Overview
      • 20.3.9.2 Product Portfolio
      • 20.3.9.3 Financials
      • 20.3.9.4 SWOT Analysis
    • 20.3.10 Inovio Pharmaceuticals Inc.
      • 20.3.10.1 Company Overview
      • 20.3.10.2 Product Portfolio
      • 20.3.10.3 Financials
      • 20.3.10.4 SWOT Analysis
    • 20.3.11 Johnson & Johnson
      • 20.3.11.1 Company Overview
      • 20.3.11.2 Product Portfolio
      • 20.3.11.3 Financials
      • 20.3.11.4 SWOT Analysis
    • 20.3.12 Merck & Co. Inc.
      • 20.3.12.1 Company Overview
      • 20.3.12.2 Product Portfolio
      • 20.3.12.3 Financials
      • 20.3.12.4 SWOT Analysis
    • 20.3.13 Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
      • 20.3.13.1 Company Overview
      • 20.3.13.2 Product Portfolio
      • 20.3.13.3 Financials
      • 20.3.13.4 SWOT Analysis
    • 20.3.14 Novavax Inc.
      • 20.3.14.1 Company Overview
      • 20.3.14.2 Product Portfolio
      • 20.3.14.3 Financials
      • 20.3.14.4 SWOT Analysis
    • 20.3.15 Panacea Biotec Ltd.
      • 20.3.15.1 Company Overview
      • 20.3.15.2 Product Portfolio
    • 20.3.16 Pfizer Inc.
      • 20.3.16.1 Company Overview
      • 20.3.16.2 Product Portfolio
      • 20.3.16.3 Financials
      • 20.3.16.4 SWOT Analysis
    • 20.3.17 Sanofi Pasteur SA (Sanofi SA)
      • 20.3.17.1 Company Overview
      • 20.3.17.2 Product Portfolio
      • 20.3.17.3 Financials
      • 20.3.17.4 SWOT Analysis
    • 20.3.18 Serum Institute of India Pvt. Ltd.
      • 20.3.18.1 Company Overview
      • 20.3.18.2 Product Portfolio
    • 20.3.19 Takeda Pharmaceutical Company Limited
      • 20.3.19.1 Company Overview
      • 20.3.19.2 Product Portfolio
      • 20.3.19.3 Financials
      • 20.3.19.4 SWOT Analysis